Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Identifying best candidates for opioid pain management among low back pain patients

19 Apr 2017

Endogenous opioid function and anger expressiveness appear to be useful in identifying chronic low back pain patients who are optimal candidates for opioid pain management, according to a study.

With the aim of addressing the lack of a sound method of identifying optimal opioid candidates, researchers examined 89 patients with chronic low back pain and 102 healthy controls. All participants underwent ischaemic pain induction under placebo, opioid blockade (naloxone) and morphine in counterbalanced order.

Anger expressiveness was evaluated using the Spielberger Anger-out subscale. Interactions among endogenous opioid function, anger-out scores and pain status in both patients and controls were evaluated with regard to morphine responses to ischaemic threshold, tolerance and pain intensity (McGill Sensory and Affective subscales), and side effects.

Results indicated that interactions between endogenous opioid function and anger-out scores identified subgroups with different patterns of morphine analgesia and side effects.

Among chronic pain patients and healthy controls, individuals with low endogenous opioid function and low anger-out scores showed the greatest morphine analgesic responses. On the other hand, the responses were relatively weaker for those with low endogenous opioid function and high anger-out scores.

Furthermore, the reported adverse effects with morphine were few among chronic pain patients with low endogenous opioid function and low anger-out scores, and many among those with low endogenous opioid function and high anger-out scores.

The current data shed light on which chronic pain patients may strike a favourable balance of good analgesia with few side effects vs those who may have an unfavourable balance of poor analgesia and many side effects.

While opioid prescriptions for chronic low back pain have increased in recent years, some patients do not achieve a satisfactory response to treatment. It is thus important to identify which patients are most likely to have a good, long-term response to opioid therapy in order to prevent unnecessary exposure to ineffective treatments or side effects. [Pain 2013;154:1038–1044; BMC Medicine 2007;5:39]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.